Thank you for Subscribing to Life Science Review Weekly Brief
Grzegorz Sarek, EG 427’s new Vice president of research, will be looking after the company’s R&D efforts.
FREMONT, CA: Grzegorz Sarek has been named Vice President of Research by EG 427. Dr. Sarek has accumulated a plethora of experience in the domains of virology, gene therapy, translational biomedicine, and cancer biology during the course of his career. He will lead the company's R&D efforts as it establishes the only European platform for gene therapy that takes use of HSV-1's innate homing and latency features.
“We are excited to welcome Grzegorz Sarek into the EG 427 team to lead our laboratory and R&D activities,” said Alberto Epstein, Ph.D., Chief Scientific Officer at EG 427. “A great addition to our team, Grzegorz is an accomplished virologist as evidenced by his impressive publication track record. He has an extensive knowledge of Herpes family viruses and a considerable experience in viral gene transfer methods using AAV-based vectors, which, together with his managing skills, are tremendous assets for EG 427 to continue developing pinpoint gene therapy.”
Dr. Sarek was the director of Gene Therapy and Translational Research at DiNAQOR AG in Zurich before joining EG 427. DiNAQOR AG develops gene therapy solutions for inherited heart disease. He was previously a Principal Scientist in the field of single-stranded oligonucleotide therapeutics at F. Hoffmann-La Roche in Basel, Switzerland, and a Group Leader in Molecular Virology at Imperial College London, UK. Dr. Sarek received his Ph.D. in Oncology and Cancer Biology from the University of Helsinki's Faculty of Medicine in Finland, and his post-doctoral training in the field of DNA Damage Response at The Francis Crick Institute in London, United Kingdom.
"I see great potential in HSV-1-based gene therapy vectors as they present clear advantages with respect to other viral vectors, both in terms of safety and of gene delivery,” explained Grzegorz Sarek, Ph.D., now Vice President of Research at EG 427. “I am therefore very enthusiastic about joining EG 427 to contribute to the development of what I see as a rigorously devised and promising HSV-1 technology vector platform, and to have the opportunity to work with a remarkable management team and founders driven by the will to solve majors medical needs.”